Derek Welsh, Founder of Psilocin and COO of Psilocin Pharma (a division of Revive Therapeutics), joins The Dales Report to talk about microdosing and what it actually means for your health and life sciences companies.
Disclaimer: The principle(s) of The Dales Report has an existing position in Revive Therapeutics. The article is neither a solicitation nor endorsement to purchase the profiled security. There is substantial risk purchasing Revive Therapeutics based on the information provided, and has been published for informational purposes only. The principle(s) may divest or make additional purchases of securities without further notice. Please contact a licensed investment advisor if you are considering investing in Revive Therapeutics.